Background
Prior to semaglutide 2.4 mg, liraglutide 3.0 mg (Saxenda) was the most effective pharmacological option for obesity management. The SCALE (Satiety and Clinical Adiposity — Liraglutide Evidence) program evaluated a higher dose of liraglutide than used for diabetes (1.2–1.8 mg) specifically for weight management.
Methods
Phase 3, double-blind, randomized, placebo-controlled trial at 191 sites in 27 countries. Adults with BMI ≥30 (or ≥27 with comorbidities) without type 2 diabetes. Liraglutide 3.0 mg or placebo, plus lifestyle intervention.
Primary endpoints: weight loss ≥5%, mean weight change, sustained weight loss (loss ≥5% at week 12 maintained through week 56).
Key Findings
| Outcome | Liraglutide 3.0 mg | Placebo |
|---|---|---|
| Mean weight loss | 8.4% | 2.8% |
| ≥5% weight loss | 63.2% | 27.1% |
| ≥10% weight loss | 33.1% | 10.6% |
| Waist circumference | −8.2 cm | −4.0 cm |
| Blood pressure improvement | Sig. reduction | — |
Clinical Significance
SCALE Obesity provided the pivotal evidence for FDA approval of liraglutide 3.0 mg (Saxenda) in December 2014 for chronic weight management. It was the first GLP-1 agonist approved specifically for obesity, establishing this drug class as a viable pharmacotherapy.
Though subsequently surpassed by semaglutide 2.4 mg in efficacy, liraglutide remains widely used and represents the proof-of-concept for GLP-1 agonism in obesity treatment.
Limitations
- Requires daily injection (vs. weekly for semaglutide/tirzepatide)
- Weight loss magnitude substantially lower than later agents
- GI side effects led to 9.9% discontinuation vs. 4.3% placebo